Annexon C1q Series: Neurodegeneration Franchise

Annexon Biosciences (Nasdaq: ANNX) invites you to its next C1q Series focusing on its Neurodegeneration Franchise and complement-mediated neurodegenerative diseases (CMND). The virtual session will be led by Annexon's executive leadership team and will feature expert thought leaders who will share their perspectives on the role of C1q and the classical complement pathway in neurodegenerative disease, including in Huntington’s disease and Amyotrophic lateral sclerosis (ALS) as well as on Neurofilament light chain (NfL) as a key clinical biomarker for neurodegeneration.